A case of tumor lysis syndrome and acute renal failure associated with elotuzumab treatment in multiple myeloma

Renal dysfunction is a common comorbidity of multiple myeloma. However, tumor lysis syndrome is a rare cause of renal dysfunction in multiple myeloma. Elotuzumab is a newly US FDA-approved monoclonal antibody used in the treatment of refractory multiple myeloma. To our knowledge, elotuzumab has not...

Descripción completa

Detalles Bibliográficos
Autores principales: Atchison, Douglas K., Humes, H. David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dustri-Verlag Dr. Karl Feistle 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715206/
https://www.ncbi.nlm.nih.gov/pubmed/29318105
http://dx.doi.org/10.5414/CNCS109165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715206/
https://www.ncbi.nlm.nih.gov/pubmed/29318105
http://dx.doi.org/10.5414/CNCS109165

Ejemplares similares